AstraZeneca records another R&D setback, triggering a meltdown at Synairgen
More than two years after AstraZeneca in-licensed Synairgen’s lead drug, the pharma giant $AZN has had to scrap a Phase IIa study of the inhaled interferon beta for asthma. And the British biotech’s stock quickly tanked on the latest snafu to afflict AstraZeneca.
The biotech said early Wednesday that AstraZeneca opted to halt the study early after determining that an overall low number of exacerbations among the asthma patients recruited would make it difficult to see if they could actually hit the primary endpoint that had been laid out. But investigators still plan to sift through the data to see how the drug did on secondary goals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
